4-[3-Cyano-4-(2-hydroxyphenyl)pyrrole-1-yl]-2-methoxymethoxy benzoic acid ethyl ester | 1072198-66-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 英文名称: 4-[3-Cyano-4-(2-hydroxyphenyl)pyrrole-1-yl]-2-methoxymethoxy benzoic acid ethyl ester
• 英文别名: ethyl 4-[3-cyano-4-(2-hydroxyphenyl)pyrrol-1-yl]-2-(methoxymethoxy)benzoate
• CAS: 1072198-66-3
• 化学式: C₂₂H₂₀N₂O₅
• 分子量: 392.411
• InChiKey: ODXSAOKAACDCDE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  29
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  93.7
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  4-[3-Cyano-4-(2-hydroxyphenyl)pyrrole-1-yl]-2-methoxymethoxy benzoic acid ethyl ester 在 盐酸 、 水 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 反应 18.0h， 生成 4-[3-Cyano-4-(2-hydroxyphenyl)pyrrole-1-yl]-2-hydroxy benzoic acid ethyl ester
  参考文献：
  名称：

  EP2133331

  摘要：

  公开号：
• 作为产物：
  描述：

  4-[4-(2-benzyloxyphenyl)-3-cyanopyrrole-1-yl]-2-methoxymethoxy-benzoic acid ethyl ester 在 palladium on activated charcoal 氢气 作用下， 以 甲醇 、 乙酸乙酯 为溶剂， 反应 5.0h， 生成 4-[3-Cyano-4-(2-hydroxyphenyl)pyrrole-1-yl]-2-methoxymethoxy benzoic acid ethyl ester
  参考文献：
  名称：

  EP2133331

  摘要：

  公开号：

文献信息

• 5-MEMBERED HETEROCYCLIC DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES
  申请人：Shimizu Kazuo

  公开号：US20100227864A1

  公开（公告）日：2010-09-09

  The present invention provides compounds useful as agents for the prevention or treatment of a disease associated with abnormal serum uric acid level which has a uricosuric activity or the like. The present invention relates to 5-membered heterocyclic derivatives represented by the following general formula (I) having xanthine oxidase inhibitory activities and useful as agents for the prevention or treatment of a disease associated with abnormality of serum uric acid level, prodrugs thereof, or salts thereof. In the formula (I), T represents nitro, cyano and the like; ring J represents aryl or heteroaryl; Q represents carboxy, 5-tetazolyl and the like; Y represents H, OH, NH 2 , halogen, haloalkyl and the like; X 1 and X 2 independently represent CR 2 or N; R 2 represents H, alkyl and the like; R 1 represents halogen, cyano, haloalkyl, A-D-E-G-L-M, -N(-D-L-M) 2 and the like, in the formula, A represents a single bond, O, S and the like; D, G and M independently represent optionally substituted alkylene, cycloalkylene, heterocycloalkylene, arylene, heteroarylene and the like; E and L independently represent a single bond, O, S, COO, SO 2 and the like.

  本发明提供了一种化合物，其具有尿酸排泄活性或类似活性，可用作预防或治疗与异常血清尿酸水平相关的疾病的药剂。本发明涉及以下通式（I）表示的具有黄嘌呤氧化酶抑制活性的5-成员杂环衍生物，其可用作预防或治疗与血清尿酸水平异常相关的疾病的药剂、其前药或其盐。在公式（I）中，T表示硝基、氰基等；环J表示芳基或杂芳基；Q表示羧基、5-四唑基等；Y表示H、OH、NH2、卤素、卤代烷基等；X1和X2独立地表示CR2或N；R2表示H、烷基等；R1表示卤素、氰基、卤代烷基、A-D-E-G-L-M、-N（-D-L-M）2等，在公式中，A表示单键、O、S等；D、G和M独立地表示可选取代的烷基、环烷基、杂环烷基、芳基、杂芳基等；E和L独立地表示单键、O、S、COO、SO2等。
• 5-MEMBERED NITROGEN CONTAINING HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME
  申请人：Shimizu Kazuo

  公开号：US20120289506A1

  公开（公告）日：2012-11-15

  5-membered heterocyclic derivatives represented by general formula (I) having xanthine oxidase inhibitory activities and useful as agents for the prevention or treatment of a disease associated with abnormality of serum uric acid level, prodrugs thereof, or salts thereof. In the formula (I), T represents nitro, cyano and the like; ring J represents aryl or heteroaryl; Q represents carboxy, 5-tetazolyl and the like; Y represents H, OH, NH 2 , halogen, haloalkyl and the like; X 1 and X 2 independently represent CR 2 or N; R 2 represents H, alkyl and the like; R 1 represents halogen, cyano, haloalkyl, A-D-E-G-L-M, —N(-D-L-M) 2 and the like, A represents a single bond, O, S and the like; D, G and M independently represent optionally substituted alkylene, cycloalkylene, heterocycloalkylene, arylene, heteroarylene and the like; E and L independently represent a single bond, O, S, COO, SO 2 and the like.

  通式（I）所表示的5元杂环衍生物具有黄嘌呤氧化酶抑制活性，并且可作为预防或治疗与血清尿酸水平异常相关的疾病的药剂，其前药或盐。在公式（I）中，T表示硝基，氰基等；环J表示芳基或杂芳基；Q表示羧基，5-四唑基等；Y表示H，OH，NH2，卤素，卤代烷基等；X1和X2独立地表示CR2或N；R2表示H，烷基等；R1表示卤素，氰基，卤代烷基，A-D-E-G-L-M，-N（-D-L-M）2等，其中A表示单键，O，S等；D，G和M分别表示可选取代的烷基，环烷基，杂环烷基，芳基，杂芳基等；E和L独立地表示单键，O，S，COO，SO2等。
• 5-membered nitrogen containing heterocyclic derivatives and pharmaceutical compositions comprising the same
  申请人：Kissei Pharmaceutical Co., Ltd.

  公开号：US08227500B2

  公开（公告）日：2012-07-24

  The present invention provides compounds useful as agents for the prevention or treatment of a disease associated with abnormal serum uric acid level which has a uricosuric activity or the like. The present invention relates to 5-membered heterocyclic derivatives represented by the following general formula (I) having xanthine oxidase inhibitory activities and useful as agents for the prevention or treatment of a disease associated with abnormality of serum uric acid level, prodrugs thereof, or salts thereof. In the formula (I), T represents nitro, cyano and the like; ring J represents aryl or heteroaryl; Q represents carboxy, 5-tetazolyl and the like; Y represents H, OH, NH2, halogen, haloalkyl and the like; X1 and X2 independently represent CR2 or N; R2 represents H, alkyl and the like; R1 represents halogen, cyano, haloalkyl, A-D-E-G-L-M, -N(-D-L-M)2 and the like, in the formula, A represents a single bond, O, S and the like; D, G and M independently represent optionally substituted alkylene, cycloalkylene, heterocycloalkylene, arylene, heteroarylene and the like; E and L independently represent a single bond, O, S, COO, SO2 and the like.

  本发明提供了化合物，其具有尿酸排泄活性或类似活性，可用作预防或治疗与异常血清尿酸水平相关的疾病的药剂。本发明涉及下式（I）表示的5-成员杂环衍生物，其具有黄嘌呤氧化酶抑制活性，并可用作预防或治疗与血清尿酸水平异常相关的疾病的药剂，其前体药物或其盐。在公式（I）中，T表示硝基，氰基等；环J表示芳基或杂芳基；Q表示羧基，5-四唑基等；Y表示H，OH，NH2，卤素，卤代烷基等；X1和X2独立地表示CR2或N；R2表示H，烷基等；R1表示卤素，氰基，卤代烷基，A-D-E-G-L-M，-N（-D-L-M）2等，在公式中，A表示单键，O，S等；D，G和M独立地表示可选取代的烷基，环烷基，杂环烷基，芳基，杂芳基等；E和L独立地表示单键，O，S，COO，SO2等。
• US8227500B2
  申请人：——

  公开号：US8227500B2

  公开（公告）日：2012-07-24
• US9023882B2
  申请人：——

  公开号：US9023882B2

  公开（公告）日：2015-05-05